research use only

SSH1 Antibody [K8K10]

Cat.No.: F1247

Application: Reactivity: Human, Mouse, Rat

Usage Information

Dilution
WB1:1000 IP1:100

Application
WB, IP

Reactivity
Human, Mouse, Rat

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
140 kDa

Datasheet & SDS

Biological Description

Specificity
SSH1 Antibody [K8K10] detects endogenous levels of total SSH1 protein.

Clone
K8K10

Synonym(s)
Protein phosphatase Slingshot homolog 1; SSH-like protein 1 (SSH-1L; hSSH-1L); SSH1; KIAA1298; SSH1L

Background
Slingshot homolog 1 (SSH1) is a dual-specificity protein phosphatase that is central to actin cytoskeleton dynamics by dephosphorylating cofilin at Ser3, thereby reactivating its F-actin severing and depolymerizing functions essential for lamellipodia protrusion, filopodia formation, cell migration, cytokinesis, and neuronal morphogenesis. SSH1 features an N-terminal regulatory domain with actin-binding motifs that allosterically stimulate phosphatase activity 14-fold upon F-actin engagement, a central catalytic phosphatase domain (Cys-X5-Arg/Ser motif, with Asp487 for phosphate coordination and Arg502 for stabilization) flanked by unstructured loops for LIMK1 substrate access, and a C-terminal F-actin binding domain (including Trp1001, Lys1023) that promotes SSH1 stabilization and actin bundling independent of its phosphatase activity. In resting cells, SSH1 is cytosolic and autoinhibited via 14-3-3 binding to phospho-Ser978, but upon Rho GTPase signaling (ROCK/PAK via LIMK/TESK-mediated cofilin phosphorylation) or integrin/FAK activation, SSH1 is dephosphorylated and translocated to the membrane, where F-actin docking exposes its active site. This enables rapid cofilin reactivation (kcat/Km ~10^6 M^-1 s^-1), generating free barbed ends for Arp2/3 nucleation, recycling G-actin for treadmilling, and balancing LIMK-mediated inactivation in a Rho/ROCK-LIMK-cofilin-SSH1 feedback circuit that regulates epithelial-to-mesenchymal transition, cancer invasion (where upregulated SSH1 correlates with metastasis in HCC and breast tumors via WNT/β-catenin crosstalk), neurodegeneration (impaired Tau clearance via SQSTM1 flux defects), and vascular permeability.

Background

Slingshot homolog 1 (SSH1) is a dual-specificity protein phosphatase that is central to actin cytoskeleton dynamics by dephosphorylating cofilin at Ser3, thereby reactivating its F-actin severing and depolymerizing functions essential for lamellipodia protrusion, filopodia formation, cell migration, cytokinesis, and neuronal morphogenesis. SSH1 features an N-terminal regulatory domain with actin-binding motifs that allosterically stimulate phosphatase activity 14-fold upon F-actin engagement, a central catalytic phosphatase domain (Cys-X5-Arg/Ser motif, with Asp487 for phosphate coordination and Arg502 for stabilization) flanked by unstructured loops for LIMK1 substrate access, and a C-terminal F-actin binding domain (including Trp1001, Lys1023) that promotes SSH1 stabilization and actin bundling independent of its phosphatase activity. In resting cells, SSH1 is cytosolic and autoinhibited via 14-3-3 binding to phospho-Ser978, but upon Rho GTPase signaling (ROCK/PAK via LIMK/TESK-mediated cofilin phosphorylation) or integrin/FAK activation, SSH1 is dephosphorylated and translocated to the membrane, where F-actin docking exposes its active site. This enables rapid cofilin reactivation (kcat/Km ~10^6 M^-1 s^-1), generating free barbed ends for Arp2/3 nucleation, recycling G-actin for treadmilling, and balancing LIMK-mediated inactivation in a Rho/ROCK-LIMK-cofilin-SSH1 feedback circuit that regulates epithelial-to-mesenchymal transition, cancer invasion (where upregulated SSH1 correlates with metastasis in HCC and breast tumors via WNT/β-catenin crosstalk), neurodegeneration (impaired Tau clearance via SQSTM1 flux defects), and vascular permeability.

References
https://pubmed.ncbi.nlm.nih.gov/36637427/ https://pubmed.ncbi.nlm.nih.gov/25187968/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%